 | |
| Type | Public |
|---|---|
| |
| Industry | synthetic biology |
| Founded | 2013 |
| Founders |
|
| Headquarters | |
| Products | Genes and gene fragments, NGS products |
| Revenue |  $54.2 million(2019)[1] |
Number of employees | 400 |
| Website | twistbioscience |
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries.[2] Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.[3]
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes.[4]
YouTube Encyclopedic
-
1/3Views:89 87249 8595 124
-
Cathie Wood’s NEW Favorite Genomic Stock Better Than Tesla???
-
ARK INVEST BOUGHT $70 MILLION OF THIS STOCK - Increased Positions By 100%
-
📈 La Mejor Oportunidad de Inversión del Año 2020 🧬👉🏻 Invertir en Twist Bioscience
Transcription
References
- ^ "Twist Bioscience | Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2019 Financial Results". investors.twistbioscience.com.
- ^ Strickland, Eliza (December 23, 2015). "DNA Manufacturing Enters the Age of Mass Production". IEEE Spectrum: Technology, Engineering, and Science News.
- ^ Yassif, Jaime; O'Prey, Kevin; Isaac, Christopher (November 2021). "Strengthening Global Systems to Prevent and Respond to High-Consequence Biological Threats" (PDF). Nuclear Threat Initiative. Archived (PDF) from the original on 2022-07-09. Retrieved 2022-07-09.
- ^ "CAD Platform Developed by GP-Write and Twist to Launch Large Genome Projects". Genetic Engineering & Technology News. May 12, 2021.
This page was last edited on 29 August 2023, at 15:30